(OBE022)
Oral, investigational and selective
prostaglandin F2 alpha
receptor antagonist
Month: June 2019
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Homepage landing image
ObsEva in the media
ObsEva Publications
View all publications